Format

Send to

Choose Destination
J Pediatr Hematol Oncol. 2014 Apr;36(3):e149-51. doi: 10.1097/MPH.0b013e318292f006.

Rituximab for the treatment of acute refractory ITP.

Author information

1
Yale University School of Medicine, New Haven, CT.

Abstract

Most children with acute immune thrombocytopenic purpura (ITP) respond to first-line therapies including intravenous immunoglobulin, corticosteroids, and Rho(D) immune globulin. However, there is no clear consensus regarding second-line therapies for the treatment of ITP, not responding to first-line therapies in the acute setting. Adapting from the chronic ITP literature, 3 patients with acute refractory ITP were treated with intravenous rituximab and showed immediate and sustained remission. Combined therapy that includes rituximab may be an effective regimen for acute refractory ITP.

PMID:
23669737
DOI:
10.1097/MPH.0b013e318292f006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center